Amgen Inc. (NASDAQ:AMGN) Shares Bought by Leibman Financial Services Inc.

Leibman Financial Services Inc. raised its position in Amgen Inc. (NASDAQ:AMGN) by 6.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 12,800 shares of the medical research company’s stock after purchasing an additional 818 shares during the period. Amgen accounts for approximately 2.4% of Leibman Financial Services Inc.’s portfolio, making the stock its 15th biggest holding. Leibman Financial Services Inc.’s holdings in Amgen were worth $3,336,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Capital Performance Advisors LLP acquired a new stake in shares of Amgen during the third quarter valued at about $25,000. Legacy Investment Solutions LLC purchased a new position in shares of Amgen during the 3rd quarter worth approximately $29,000. Hershey Financial Advisers LLC acquired a new stake in Amgen in the 2nd quarter valued at approximately $30,000. Matrix Trust Co purchased a new stake in Amgen in the third quarter valued at approximately $36,000. Finally, Livelsberger Financial Advisory acquired a new position in Amgen during the third quarter worth $56,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of several research analyst reports. Sanford C. Bernstein started coverage on Amgen in a report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective on the stock. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Truist Financial dropped their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Leerink Partners reduced their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Finally, Royal Bank of Canada dropped their price target on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Trading Up 3.0 %

Shares of Amgen stock opened at $270.19 on Tuesday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The business has a 50 day moving average price of $278.16 and a 200 day moving average price of $308.35. The company has a market capitalization of $145.24 billion, a P/E ratio of 34.60, a P/E/G ratio of 2.91 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the business earned $4.96 earnings per share. Sell-side analysts anticipate that Amgen Inc. will post 19.53 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.52%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is presently 121.90%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.